is retatrutide bad Promises Big Weight Loss, but Safety Remains a Question Retatrutide: breakthrough… or still too

Its a complementary therapy, not a replacement

Consider these key trends transforming the healthcare ecosystem: Massive Addressable Market : With over 40% of Americans classified as obese and another 30% overweight, the potential user base for GLP-1 therapies and related services exceeds 100 million people in the U.S

GLP-1 receptor agonists such as semaglutide can help manage blood glucose, body weight, and certain cardiometabolic risks when prescribed for an appropriate patient

Many people report: Less interest in food Reduced snacking Better portion control Improved dietary consistency Some early weight loss may begin to occur